Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival
Restricted accessResearch articleFirst published online October, 2019
Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival
Thrombocytopaenia and autoimmune haemolytic anaemia (AIHA) have considerable impact on prognosis in systemic lupus erythematosus (SLE). We investigated the frequencies of these haemocytopaenias, along with their associations and effect on outcome in a single-centre cohort of patients with SLE.
Methods
Demographic characteristics, clinical features, autoantibody profiles, damage and mortality data were compared between patients with and without each haematological abnormality. Variables displaying significant differences between the groups were entered into logistic regression.
Results
Ninety-three patients had AIHA and 215 had thrombocytopaenia. Both were associated with neuropsychiatric (NP) involvement, with each other, leucopaenia, antiphospholipid syndrome (APS) and antiphospholipid antibodies. More patients in both groups had organ damage, and their damage scores were higher. Association to NP damage was discernible. In addition, cardiovascular and renal damage and diabetes were more pronounced in patients with thrombocytopaenia. At logistic regression analysis, younger age, anticardiolipin antibody IgM positivity, leucopaenia and thrombocytopaenia were associated with AIHA whilst lupus anticoagulant activity, AIHA, leucopaenia, APS and NP involvement were associated with thrombocytopaenia. Among damage items, peripheral vascular damage, diabetes, NP damage, renal and ocular damage displayed significant associations with thrombocytopaenia, whereas none of the items did with AIHA. Patients with AIHA had significantly reduced survival rates at 10 and 20 years.
Conclusions
We observed that AIHA and thrombocytopaenia were associated with severe lupus, affecting major organs and causing end organ damage. Thus, they may be considered as prognostic markers. Furthermore, AIHA and especially thrombocytopaenia may also be a marker for a subgroup of lupus patients who have or may develop APS.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol1997; 40: 1725–1725.
2.
PetriMOrbaiAMAlarconGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2012; 64: 2677–2686.
3.
CerveraRKhamashtaMAFontJ, et al.Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)1999; 78: 167–175.
4.
MokCCLeeKWHoCTLauCSWongRW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford)2000; 39: 399–406.
5.
VilaLMAlarcanGSMcGwinGJr, et al.Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford)2004; 43: 358–363.
6.
MichelMLeeKPietteJC, et al.Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol2002; 119: 354–358.
7.
ZiakasPDRoutsiasJGGiannouliSTasidouATzioufasAGVoulgarelisM. Suspects in the tale of lupus-associated thrombocytopenia. Clin Exp Immunol2006; 145: 71–80.
8.
Artim-EsenBDiz-KüçükkayaRİnançM. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep2015; 17: 14–14.
9.
ZiakasPDGiannouliSZintzarasETzioufasAGVoulgarelisM. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis2005; 64: 1366–1369.
10.
GiannouliSVoulgarelisMZiakasPDTzioufasAG. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis2006; 65: 144–148.
11.
Alarcon-SegoviaDDelezeMOriaCV, et al.Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore)1989; 68: 353–365.
12.
HazeltineMRauchJDanoffDEsdaileJMTannenbaumH. Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs’ and hypocomplementemia. J Rheumatol1988; 15: 80–86.
13.
CerveraRFontJLopez-SotoA, et al.Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis1990; 49: 109–113.
14.
TektonidouMGIoannidisJPABokiKAVlachoyiannopoulosPGMoutsopoulosHM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med2000; 93: 523–530.
15.
JeffriesMHamadehFAberleT, et al.Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective. Lupus2008; 17: 739–743.
16.
SultanSMBegumSIsenbergDA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford)2003; 42: 230–234.
17.
GladmanDGinzlerEGoldsmithC, et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheumatol1996; 39: 363–369.
18.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
19.
Velo-GarcíaAGuerreiro CastroSIsenbergDA. The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun2016; 74: 139–160.
20.
KuwanaMKaburakiJOkazakiY, et al.Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford)2006; 45: 851–854.
21.
KarpouzasGAHematological and lymphoid abnormalities in SLE. In: WallaceDHahnB (eds). DUBOIS’ lupus erythematosus and related syndromes, 8th ed. Philadelphia, PA: Elsevier, 2013, pp. 426–437.
22.
EspinolaRGPierangeliSSGharaviAE, et al.Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost2002; 87: 518–522.
23.
LuttersBCMeijersJCDerksenRH, et al.Dimers of beta 2- glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I- anti-beta 2-glycoprotein I antibody complexes. J Biol Chem2001; 276: 3060–3067.
24.
Lopez-SotoACerveraRFontJ, et al.Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin Exp Rheumatol1997; 15: 143–149.
25.
Abu-ShakraMGladmanDDUrowitzMBFarewellV. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med1995; 99: 624–628.
26.
Artim-EsenBCeneESahinkayaY, et al.Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol2014; 41: 1304–1310.
27.
MillerMHUrowitzMBGladmanDD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum1983; 26: 1181–1186.
28.
CerveraRTektonidouMGEspinosaG, et al.Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus2011; 20: 174–181.
29.
WardMMPyunEStudenskiS. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med1996; 56: 1337–1344.
30.
PistinerMWallaceDJNessimSMetzgerALKlinenbergJR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum1991; 21: 55–64.
31.
NivedOJonsenABengtssonAABengtssonCSturfeltG. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol2002; 29: 1398–1400.
32.
FontJCerveraRRamos-CasalsM, et al.Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum2004; 33: 217–230.
33.
NewmanKOwliaMBEl-HemaidiIAkhtariM. Management of immune cytopenias in patients with systemic lupus erythematosus – old and new. Autoimmun Rev2013; 12: 784–791.
34.
LangBStraubRHWeberSRotherEFleckMPeterHH. Elevated anticadiolipin antibodies in autoimmune haemolytic anaemia irrespective of underlying systemic lupus erythematosus. Lupus1997; 6: 652–655.
35.
ChengHM. IgG antiphospholipid autoantibody in normal human sera is reactive against bromelain treated human erythrocytes. J Rheumatol1993; 20: 400–401.
36.
UthmanIGodeauBTaherAKhamashtaM. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev2008; 22: 187–194.
37.
ShoenfeldY. Autoimmune hemolytic anemia in the antiphospholipid syndrome. Lupus2006; 15: 473–477.
38.
HoffmanPC. Immune hemolytic anemia – selected topics. Hematology Am Soc Hematol Educ Program2006, pp. 13–18.
39.
KokoriSIIoannidisJPVoulgarelisMTzioufasAGMoutsopoulosHM. Autoimmune hemolytic anemia in patients with SLE. Am J Med2000; 108: 198–204.
40.
VoulgarelisMKokoriSIIoannidisJPTzioufasAGKyriakiDMoutsopoulosHM. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis2000; 59: 217–222.
41.
DomicianoDSShinjoSK. Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. Clin Rheumatol2010; 29: 1427–1431.
42.
DuranSApteMAlarconGS, et al.Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort. Arthritis Rheumatol2008; 59: 1332–1340.
